Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025. Read More
Amgen reports strong Q4 growth amid expanding product sales and biotech innovations
Amgen’s revenue growth for the fourth quarter of 2024 exceeded analyst expectations, reflecting the company’s expanding biopharmaceutical portfolio and solid market positioning. The biotechnology giant ... Read More
FDA approves Amgen’s Repatha for heart attack and stroke prevention
In a significant advancement for cardiovascular disease management, Amgen's Repatha (evolocumab) has received approval from the U.S. Food and Drug Administration (FDA) to prevent heart ... Read More
Amgen’s Repatha proves effective in major cardiovascular outcomes study
Amgen Inc. has achieved a significant milestone with its cholesterol-lowering injection, Repatha (evolocumab), demonstrating a 20% reduction in heart attack and stroke risks among patients ... Read More